Healthy male/female adults
Conditions
Interventions
None listed
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Healthy male/female Individuals ranging in age from 20 to 59, at informed consent. (2) Individuals who can give informed consent to take part in this research, after being provided with an explanation of the protocol detail.
Exclusion criteria
Exclusion criteria: (1) Individuals being under some kind of continuous medical treatment, except applying a nasal spray and eye drops. (2) Individuals who took a steroid within the last three months from the time point of clinic visiting. (3) Individuals who apply a steroid all the year around, except a seasonal use and deteriorating conditions. (4) Individuals who were vaccinated within the past two weeks to the clinic visiting. (5) Individuals touching excessive alcohol. (6) Individuals with serious drug and/or food allergy. (7) Individuals who are under the other clinical tests with some kind of medicine/food, or participated in those within four weeks after this research. (8) Individuals with previous and/or current medical history of serious diseases in heart, liver, kidney and/or digestive organs. (9) Females who are pregnant or lactating. (10) Individuals who donated 200 mL of their blood or blood components within the last month. (11) Individuals who donated 400 mL of his blood within the last 3 months. (12) Individuals who donated 400 mL of her blood within the last 4 months. (13) Individuals who have had a total of 1200 mL of his blood collected within the last 12 months, including in this study. (14) Individuals who have had a total of 800 mL of her blood collected within the last 12 months, including in this study. (15) Individuals deemed unsuitable for participation in the trial by the principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Counts of white blood cell, red blood cell, and platelet | — |
Secondary
| Measure | Time frame |
|---|---|
| Examinations of blood cell - - (1) expressing protein (conventional/ghost flow cytometry), (2) form (conventional/ghost flow cytometry, and microscopic observation), (3) proliferation (general cell counting, or conventional/ghost flow cytometry), (4) differentiation induction (conventional/ghost flow cytometry, microscopic observation, reverse transcription-polymerase chain reaction, and ribonucleic acid-sequencing), (5) function (conventional/ghost flow cytometry), (6) secretary protein (enzyme-linked immunosorbent assay), (7) drug response (conventional/ghost flow cytometry, microscopic observation, reverse transcription-polymerase chain reaction, and ribonucleic acid-sequencing), (8) gene expression (reverse transcription-polymerase chain reaction, and ribonucleic acid sequencing), (9) gene function (conventional/ghost flow cytometry, reverse transcription-polymerase chain reaction, and ribonucleic acid-sequencing) - - . | — |
Countries
Japan
Contacts
Public ContactMasanori Numa
CPCC Company Limited Clinical Planning Department
Outcome results
None listed